Clinical Trials Logo

Clinical Trial Summary

In this study the researchers want to investigate genetic polymorphisms of cytochrome 450 enzymes and the multiple drug resistance (MDR) gene in renal transplant patients to look for differences in dosing of immunosuppressive drugs (tacrolimus, sirolimus, everolimus, cyclosporine A).

All patients who receive one of these drugs can be included and drug blood trough levels, dosing and genetics are compared.


Clinical Trial Description

Primary endpoint is the

1. serum creatinine in patients with and without polymorphysms

2. rate of rejections in patients with and without polymorphysms ;


Study Design

Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT00223054
Study type Observational
Source University of Schleswig-Holstein
Contact
Status Completed
Phase Phase 4
Start date March 2005
Completion date October 2006

See also
  Status Clinical Trial Phase
Completed NCT01443013 - Analysis of Foxp3 and Vimentin Expression in Renal Transplant Recipient N/A
Completed NCT01759862 - Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant N/A
Active, not recruiting NCT01095172 - RituxiMab INDuction in Renal Transplantation Phase 4
Terminated NCT01292525 - Protocol Calcineurin Inhibitor (CNI) Weaning Phase 3